NY-ESO-1/LAGE-1基因在肝癌组织中的表达及其诱导的体液免疫应答

Expression of NY-ESO-1/LAGE-1 genes in hepatocellular carcinoma and autologous humoral responses induced thereby

目的 检测肿瘤特异性共享抗原NY ESO 1/LAGE 1基因在肝癌中的表达情况及其诱导肝癌患者体液免疫应答的能力 ,为利用NY ESO 1/LAGE 1为抗原进行肝癌的疫苗免疫治疗提供依据。方法 利用逆转录 聚合酶链反应 (RT PCR)方法检测了 34例肝癌患者癌和癌旁组织NY ESO 1/LAGE 1基因mRNA水平的表达 ;利用酶联免疫吸附实验检测了NY ESO 1/LAGE 1在 37例肝癌患者中诱导自身抗体产生的能力。结果 34例肝癌组织中 9例 ( 2 6 .5 % )表达NY ESO 1,12例 ( 35 3% )表达LAGE 1。其中 ,同一标本中共表达NY ESO 1/LAGE 1的病例数为 7例 ;表达其中至少一种基因的14例 ,占总数的 4 1.2 %。所检测的 37份肝癌患者血清中 ,6例患者血清抗NY ESO 1抗体阳性 ,5例为Ⅲ期及以上患者 ,1例为Ⅱ期患者。结论 NY ESO 1/LAGE 1在肝癌患者中表达率较高 ,并可诱导自身体液免疫应答 。

Objective To investigate the potential of utilizing NY-ESO-1/LAGE-1 antigens in hepatocellular carcinoma (HCC) vaccines. Methods RT-PCR method was used to detect the expression of NY-ESO-1/LAGE-1 mRNA in the cancerous tissues and adjacent tissues resected from 34 patients with HCC. ELISA assay was adopted to analyze the NY-ESO-1 specific antibodies in 37 serum samples of HCC patients, 1 positive control sample, and 8 samples of normal persons. Results Nine (26 5%) out of the 34 HCC samples were NY-ESO-1 mRNA positive, while 12 (35 3%) were LAGE-1 positive. Among them, seven HCC samples expressed both genes, and 14 (41 6%) expressed at least one of the genes. Among the 37 serum samples tested six contained high titer of anti-NY-ESO-1 antibodies. Five of the samples were from stage Ⅲ or later stage HCC patients; one was from a stage Ⅱ patient. Conclusion NY-ESO-1 /LAGE-1 mRNA is expressed in a high frequency in HCC tissue samples, and induces autologous humoral responses in HCC patients. Both of the antigens can be considered as candidates for HCC vaccines.